Our study demonstrates that regardless of breast cancer subtype or specific IO target, patients with metastatic breast cancer (TNBC or endocrine-resistant HR-positive/HER2-negative) treated with combinations of IO plus chemotherapy had prolonged PFS and OS compared to patients treated with IO agents alone. This evidence concerns the gene ERBB2 and breast carcinoma.